Organogenesis Holdings

Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Organogenesis Holdings reports Q4 revenue decline but exceeds guidance

Organogenesis Holdings faced revenue decline in Q4 2022 but exceeded guidance expectations.
Operational progress in clinical trials and a healthy cash position are notable strengths.
Challenges include declining product sales and increased operating expenses.
Strategic investments and growth opportunities in clinical initiatives are key focus areas for 2023.

Organogenesis Holdings reports robust Q1 revenue growth and strategic focus

Organogenesis Holdings delivered strong revenue growth driven by Advanced Wound Care products, while facing challenges with increased expenses and a net loss.
The company's focus on innovation, market expansion, and cost management presents opportunities for sustained growth and competitive positioning.
Navigating regulatory requirements and market dynamics will be crucial for Organogenesis to capitalize on opportunities and mitigate challenges in the upcoming quarters.

Organogenesis Holdings faces revenue challenges amidst strong business trends

Organogenesis Holdings faced revenue challenges due to LCDs impacting products, leading to withdrawn guidance. Despite this, the company maintained a strong gross profit margin and focused on strategic sales shifts. Opportunities for growth exist in product focus and ongoing trials.

Organogenesis reports Q3 revenue decline, eyes growth amid regulatory shifts

Organogenesis Holdings navigated challenges in Q3 2023 with a focus on operational efficiency, financial strength, and strategic growth initiatives for the future.
While facing revenue declines and market uncertainties, the company capitalized on positive regulatory developments and operational advancements to drive performance.
Looking ahead, Organogenesis aims to address challenges, seize growth opportunities, and maintain its competitive edge in the evolving healthcare market landscape.

Organogenesis Holdings reports Q4 revenue decline but anticipates 2024 growth

Organogenesis Holdings faced challenges in Q4 but showed positive momentum and progress in clinical trials. The company expects revenue growth in 2024 and is focusing on customer engagement and new product launches for further expansion.

Organogenesis Holdings beats revenue expectations, eyes FDA approval for ReNu

Organogenesis Holdings demonstrated solid financial performance in Q1, with revenue exceeding expectations and improved operating metrics.
While facing challenges in certain revenue segments, the company's focus on innovation and regulatory progress presents growth opportunities.
Maintaining a strong cash position and reaffirming revenue guidance underscore Organogenesis' resilience and strategic outlook for the future.

Organogenesis Holdings exceeds Q3 revenue guidance, focuses on innovation

Organogenesis Holdings delivered a strong performance in Q3 2024, surpassing revenue guidance and demonstrating solid financial results.
While facing challenges such as potential market disruption and regulatory issues, the company remains focused on strategic initiatives and innovation to drive growth.
With opportunities in Medicare reimbursement, product development, and regulatory milestones, Organogenesis is well-positioned for future success and revenue expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Organogenesis (ORGO) is a Great Choice

Cal-Maine Foods

Cloudflare

ORGO, CALM and NET made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 5, 2024.

Best Momentum Stocks to Buy for January 5th

Evolent Health

Wayfair

ORGO, CALM, W, NET and EVH have been added to the Zacks Rank #1 (Strong Buy) List on January 5, 2024.

New Strong Buy Stocks for January 5th

Organogenesis (ORGO) is a Great Momentum Stock: Should You Buy?

Hooker Furniture

Riskified Ltd

Stoneridge

VirTra

Small-cap stocks should rally ahead due to cheaper valuation, cooling inflation data and hopes of Fed rate cuts in 2024. Against this backdrop, Organogenesis (ORGO), Riskified (RSKD), Hooker Furniture Corporation (HOFT), Stoneridge (SRI) and VirTra (VTSI) emerge as winning picks.

5 Reasons Why Small-Cap Stocks Can Surge in 2024: 5 Top Picks

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Organogenesis Holdings, Inc. (NASDAQ: ORGO) on behalf of long-term stockholders following a class action complaint that was filed against Organogenesis on December 10, 2021 with a Class Period from March 17, 2021 to October 11, 2021. Our investigation concerns whether the board of directors of Organogenesis have breached their fiduciary dutie.

ORGANOGENESIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Organogenesis Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Organogenesis (ORGO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Here Is Why Bargain Hunters Would Love Fast-paced Mover Organogenesis (ORGO)

Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q3 2023 Earnings Conference Call November 9, 2023 5:00 PM ET Company Participants Gary Gillheeney - President, CEO & Chair David Francisco - CFO Conference Call Participants Ryan Zimmerman - BTIG Operator Welcome, ladies and gentlemen, to the Third Quarter of Fiscal Year 2023 Earnings Conference Call for Organogenesis Holdings Inc. [Operator Instructions]. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly.

Organogenesis Holdings, Inc. (ORGO) Q3 2023 Earnings Call Transcript

CANTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30th, 2023.

Organogenesis Holdings Inc. Reports Third Quarter 2023 Financial Results

CANTON, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that third quarter of fiscal year 2023 financial results will be reported after the market closes on Thursday, November 9th.

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023

Organogenesis focuses on advanced wound products. The company's second-quarter revenue and net income were down year over year.

Why Shares of Organogenesis Holdings Are Up Thursday

CANTON, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, applauds today's decision by the three Medicare Administrative Contractors (MACs) to withdraw the final local coverage determinations (LCDs) for Skin Substitute Grafts/Cellular and/or Tissue-Based Products for the Treatment of Diabetic Foot Ulcers (DFU) and Venous Leg Ulcers (VLU) scheduled to take effect on October 1.

Organogenesis Applauds Withdrawal of Local Coverage Determinations by Novitas, First Coast Service Options and CGS

CANTON, Mass. , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that company management will participate in the Morgan Stanley 21st Annual Global Healthcare Conference, which is being held at the Sheraton New York Times Square Hotel in New York, NY from September 11th-13th. Management will host a fireside chat to discuss business matters on Monday, September 11th at 8:00 a.m. Eastern Time.

Organogenesis Holdings Inc. to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Organogenesis saw revenue and net income drop year over year. The company withdrew annual guidance.

Why Shares of Organogenesis Holdings Are Dropping Thursday

CANTON, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30th, 2023.

Organogenesis Holdings Inc. Reports Second Quarter 2023 Financial Results; Withdraws Fiscal Year 2023 Guidance

Blade Air Mobility

The Metals Co

While the market offers ample opportunities for wild speculation, there's something about favored penny stocks by analysts that arouses interest. Don't get me wrong – whenever you're dealing with enterprises in this troubled arena, downside threats are never too far away.

3 Penny Stocks That Wall Street Analysts Can't Get Enough Of

Organogenesis is a solid player in the surgical care product market. Over its long existence, it has developed an important slate of core competencies. Small-cap biotech is a risky area, none more so than Organogenesis.

Organogenesis: Solid Revenue Generation From A Hyper-Trading Wound Care Company

Dragonfly Energy Holdings Corp

Canoo

Rigel Pharmaceuticals

Rockwell Medical

Interested in discovering the top penny stocks to invest in? You're certainly not the only one.

7 Cheap Penny Stocks to Buy According To Analysts, Targets Up To 1,090%

Want to know how to find the best penny stocks to buy now? Of course you do and you're not alone.

4 Cheap Penny Stocks to Buy According To Analysts, Targets Up To 230%

CANTON, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that second quarter of fiscal year 2023 financial results will be reported after the market closes on Wednesday, August 9th.

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2023 Financial Results on August 9, 2023

An analyst updated Organogenesis' price target. Competitor Integra LifeSciences said Tuesday it was recalling a product.

Why Shares of Organogenesis Climbed Wednesday

Cabaletta Bio

Community Health Systems

Exact Sciences

Moderna

Novavax

Pfizer

Ultragenyx Pharmaceutical

Viking Therapeutics

TipRanks' analyst ranking service ranks the top Wall Street firms of the past decade.

TipRanks reveals the top 10 health care sector analysts of the past decade

Organogenesis said it expects sales to rise between 1% and 3% this year. The company said revenue rose by 10% year over year in the first quarter.

Why Shares of Organogenesis Holdings Jumped Thursday

Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q1 2023 Earnings Conference Call May 10, 2023 5:00 PM ET Company Participants Gary Gillheeney - President and CEO Dave Francisco - CFO Conference Call Participants Ryan Zimmerman - BTIG Operator Welcome, ladies and gentlemen to the First Quarter of Fiscal Year 2023 Earnings Conference Call for the Organogenesis Holdings Inc. At this time, all participants have been placed in a listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly.

Organogenesis Holdings Inc. (ORGO) Q1 2023 Earnings Call Transcript

CANTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2023.

News for Organogenesis Holdings Stock (ORGO)